KRAS and neoplasm: While K‐Ras mutations and amplifications do occur in primary BTC, the collective frequency of these events in the cell line panel (45%) is significantly greater than that observed in primary cancers (18%) (Nakamura et al., 2015), suggesting that tumours harbouring these genetic alterations may be more amenable to cell line generation.